Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

Despite falling short of previously announced targets Novo Nordisk is still positive on meeting the primary endpoint of ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Novo Nordisk NVO shares have plunged 17.9% in a ... after the regulatory body determined that LLY’s supply is currently meeting or exceeding demand and will continue to do so in the future.

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00 ...

Ozempic maker Novo Nordisk A/S took two large steps toward meeting demand for its blockbuster drugs, committing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark shortly after it ...

Despite falling short of previously announced targets Novo Nordisk is still positive on meeting the primary endpoint of efficacy over placebo. Martin Holst Lange, executive vice president for ...